Promoter Hypermethylation Is the Predominant Mechanism in hMLH1 and hMSH2 Deregulation and Is a Poor Prognostic Factor in Nonsmoking Lung Cancer

• Published in: Clinical cancer research Vol. 11; no. 15; pp. 5410 - 5416
• Main Authors: Hsu, Han-Shui, Wen, Chiao-Kai, Tang, Yen-An, Lin, Ruo-Kai, Li, Wing-Yin, Hsu, Wen-Hu, Wang, Yi-Ching
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Association for Cancer Research 01.08.2005
• Subjects: Adult; Aged; Antineoplastic agents; Biological and medical sciences; Carcinoma, Non-Small-Cell Lung - diagnosis; Carcinoma, Non-Small-Cell Lung - genetics; DNA Methylation; DNA Restriction Enzymes - chemistry; DNA Restriction Enzymes - pharmacology; Female; gene; Gene Expression Regulation, Neoplastic; hMLH1; hMSH2; Humans; Immunohistochemistry; Lung Neoplasms - diagnosis; Lung Neoplasms - genetics; Medical sciences; Middle Aged; Neoplasm Metastasis; NSCLC; Pharmacology. Drug treatments; Pneumology; Polymerase Chain Reaction; Prognosis; promoter hypermethylation; Promoter Regions, Genetic; Smoking; Time Factors; Treatment Outcome; Tumors of the respiratory system and mediastinum; Lung disease; Prognosis; Respiratory disease; Transcription promoter; Lung cancer; Mechanism of action; Methylation; Bronchopulmonary; Repair gene

Purpose and Experimental Design: The etiologic association and prognostic significance of mismatch repair gene/protein alterations have never been examined in nonsmoking lung cancer. Therefore, we investigated protein expression and promoter hypermethylation of hMLH1 and hMSH2 genes in the tumor spe...